BDSI reported net revenue of $62.0 million for 2017, compared to $15.5 million for the year prior. "2017 was an important year for BDSI and one of great change," said Scott Plesha, president of BDSI, on the company's quarterly and full-year financial results call Thursday afternoon.

In a release issued under the same headline earlier today by BioDelivery Sciences International, Inc., please note that in the second bullet of the Corporate section, the end date of the non-exclusive ...

The Raleigh, North Carolina-based company said it had a loss of 29 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

NEW YORK, NY / ACCESSWIRE / March 15, 2018 / BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at ...

BioDelivery Sciences International Inc (NASDAQ:BDSI) delivered an ROE of 29.45% over the past 12 months, which is an impressive feat relative to its industry average of 10.88% during the sameRead More...

RALEIGH, N.C., March 14, 2018-- BioDelivery Sciences International, Inc., a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that Scott Plesha, President ...

RALEIGH, N.C., March 07, 2018-- BioDelivery Sciences International, Inc., a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that it will report ...

RALEIGH, N.C., March 05, 2018-- BioDelivery Sciences International, Inc., a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that Scott Plesha, President ...

United Therapeutics has settled patent litigation over a $157 million drug. The company (UTHR) reached an agreement with Actavis Laboratories FL, which is a subsidiary of generic giant Teva Pharmaceuticals, that resolves litigation over certain patents related to one of United Therapeutics' pulmonary arterial hypertension drugs: Orenitram. The settlement agreement allows Actavis to begin manufacturing and commercializing a generic version of the drug in June 2027 or potentially earlier under some circumstances. However, United Therapeutics noted that the agreement doesn't allow Actavis to manufacture generic versions of other products like Tyvaso or Remodulin.

NEW YORK, Feb. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Great ...

RALEIGH, N.C., Jan. 30, 2018--. BioDelivery Sciences International, Inc. and Purdue Pharma announced today that BELBUCA ® buccal film is now commercially available in Canada. The first commercial sale ...

Savara, Inc. , an orphan lung disease company, today announced that Peter Ginsberg has joined the company as Vice President of Business Development. An accomplished orphan lung disease business development ...

Following Raleigh-based BioDelivery Sciences International’s (BDSI) announcement of longtime president and CEO Dr. Mark Sirgo’s planned retirement , Scott Plesha, BDSI’s new president, effective Jan. 2 , says the company will expand its sales force in 2018. With offers out in the current quarter, Plesha says he expects the majority of the new hires to be trained in January and up and running in February. “One of the things that was really important for us in 2017 was the ability to show that we’re able to grow Belbuca [the company’s pain management product it reacquired from Endo Pharmaceuticals earlier this year ] in a market that is contracting year over year,” says Plesha.

RALEIGH, N.C., Dec. 20, 2017-- BioDelivery Sciences International, Inc. announced the appointment of Scott Plesha, currently Senior Vice President of Sales and Marketing at BDSI, to the role of President, ...